Tocilizumab (Actemra)

Drug Name: Tocilizumab (Actemra)
Company: Genentech
Drug Type: Protein Biologic
Conditions: ALS, Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis (PJIA)
Mechanism Type: Immunomodulation
Mechanism: Tocilizumab may reduce neuroinflammation by lowering levels of the pro-inflammatory cytokine IL-6. The drug, which is a monoclonal antibody, competitively inhibits the binding of interleukin-6 (IL-6) to its receptor.
U.S. Status for ALS: Phase II

[1] Fiala, M. et al. Tocilizumab infusion therapy normalizes inflammation in sporadic ALS patients. Am J Neurodegener Dis. 2013 Jun 21;2(2):129-39.

Last updated June 22nd, 2017

Share this: